Wells Fargo Analyst Maintains Hold Rating on Kezar Life Sciences

Wells Fargo analyst Derek Archila maintained a Hold rating on Kezar Life Sciences with a price target of $7.00. Kezar Life Sciences has a Moderate Buy analyst consensus and a price target consensus of $7.00. The company's market cap is $29.15M with a P/E ratio of -0.41.

Analysts from various financial institutions have recently provided their insights on Kezar Life Sciences Inc (KZR), with mixed ratings and price targets. William Blair analyst Matt Phipps maintains a Buy rating with a price target of $7.00 [1], while Wells Fargo analyst Derek Archila has a Hold rating with the same price target [2]. The current analyst consensus is a Moderate Buy with a price target consensus of $7.00 [2].

Kezar Life Sciences reported a quarterly adjusted loss of $1.87 per share for the quarter ended June 30, 2025, which was higher than the same quarter last year when the company reported EPS of $-2.70 [2]. The mean expectation of six analysts for the quarter was for a loss of $2.39 per share, and Wall Street expected results to range from $-2.78 to $-2.04 per share [2]. The company reported a quarterly loss of $13.7 million, with revenue of zero as expected by analysts [2].

The company's cash position has decreased to $100.8 million as of June 30, 2025, from $132.2 million as of December 31, 2024, primarily due to cash used in operations [2]. Despite the financial setbacks, Kezar Life Sciences has maintained a Moderate Buy analyst consensus with a price target of $7.00, indicating a cautious optimism among investors [2].

Kezar Life Sciences has a market capitalization of $29.15M with a P/E ratio of -0.41 [2]. The company's stock has fallen by 14.8% this quarter and lost 42.0% so far this year [2]. The current average analyst rating on the shares is "buy," with a breakdown of 3 "strong buy" or "buy," 3 "hold," and no "sell" or "strong sell" [2]. Wall Street's median 12-month price target for Kezar Life Sciences Inc is $12.50, about 68.8% above its last closing price of $3.90 [2].

The company's recent financial performance and analyst ratings suggest a mixed outlook for Kezar Life Sciences. While the company has faced financial challenges, the analyst consensus remains cautiously optimistic. Investors should closely monitor the company's progress and upcoming earnings reports to gauge its future performance.

References:
[1] https://www.ainvest.com/news/kezar-life-sciences-maintains-buy-rating-william-blair-2508/
[2] https://seekingalpha.com/news/4483609-arcturus-outlines-pivotal-trial-plans-and-advances-cf-and-otc-programs-with-regulatory